Orthogeriatrics and Hip Fracture Care in the UK: Factors Driving Change to More Integrated Models of Care

por Middleton, Mark
Publicado 2018

Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment

por Zhu, Winston M, Middleton, Mark R
Publicado 2023

Genetic Biomarkers of Barrett’s Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis

por Findlay, John M., Middleton, Mark R., Tomlinson, Ian
Publicado 2015

Erratum to: Genetic Biomarkers of Barrett’s Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis

por Findlay, John M., Middleton, Mark R., Tomlinson, Ian
Publicado 2016

Genetic susceptibility to Barrett’s oesophagus: Lessons from early studies

por Findlay, John M, Middleton, Mark R, Tomlinson, Ian
Publicado 2015

Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report

por Dooley, Andrew J., Gupta, Avinash, Middleton, Mark R.
Publicado 2016

Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis

por Toor, Kabirraaj, Middleton, Mark R., Chan, Keith, Amadi, Adenike, Moshyk, Andriy, Kotapati, Srividya
Publicado 2021

Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals

por Morrell, Liz, Wordsworth, Sarah, Schuh, Anna, Middleton, Mark R., Rees, Sian, Barker, Richard W.
Publicado 2018

Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals

por Morrell, Liz, Wordsworth, Sarah, Schuh, Anna, Middleton, Mark R., Rees, Sian, Barker, Richard W.
Publicado 2019

Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT

por Nwolise, Chidiebere, Corrie, Pippa, Fitzpatrick, Ray, Gupta, Avinash, Jenkinson, Crispin, Middleton, Mark, Matin, Rubeta
Publicado 2021

Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives

por Middleton, Mark R., Hoeller, Christoph, Michielin, Olivier, Robert, Caroline, Caramella, Caroline, Öhrling, Katarina, Hauschild, Axel
Publicado 2020

Societal preferences for adjuvant melanoma health states: UK and Australia

por Middleton, Mark R., Atkins, Michael B., Amos, Kaitlan, Wang, Peter Feng, Kotapati, Srividya, Sabater, Javier, Beusterien, Kathleen
Publicado 2017

Invariant NKT cells modulate the suppressive activity of Serum Amyloid A-differentiated IL-10-secreting neutrophils

por De Santo, Carmela, Arscott, Ramon, Booth, Sarah, Karydis, Ioannis, Jones, Margaret, Asher, Ruth, Salio, Mariolina, Middleton, Mark, Cerundolo, Vincenzo
Publicado 2010

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

por Andtbacka, Robert H. I., Collichio, Frances, Harrington, Kevin J., Middleton, Mark R., Downey, Gerald, Ӧhrling, Katarina, Kaufman, Howard L.
Publicado 2019

Immunophenotypes of pancreatic ductal adenocarcinoma: Meta‐analysis of transcriptional subtypes

por de Santiago, Ines, Yau, Christopher, Heij, Lara, Middleton, Mark R., Markowetz, Florian, Grabsch, Heike I., Dustin, Michael L., Sivakumar, Shivan
Publicado 2019

Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence

por Findlay, John M., Dickson, Edward, Fiorani, Cristina, Bradley, Kevin M., Mukherjee, Somnath, Gillies, Richard S., Maynard, Nicholas D., Middleton, Mark R.
Publicado 2019

Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (Ther...

por Spiers, Laura, Gray, Michael, Lyon, Paul, Sivakumar, Shivan, Bekkali, Noor, Scott, Shaun, Collins, Linda, Carlisle, Robert, Wu, Feng, Middleton, Mark, Coussios, Constantin
Publicado 2023

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma

por Helfrich, Iris, Scheffrahn, Inka, Bartling, Sönke, Weis, Joachim, von Felbert, Verena, Middleton, Mark, Kato, Masahi, Ergün, Süleyman, Augustin, Hellmut G., Schadendorf, Dirk
Publicado 2010

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma

por Helfrich, Iris, Scheffrahn, Inka, Bartling, Sönke, Weis, Joachim, von Felbert, Verena, Middleton, Mark, Kato, Masahi, Ergün, Süleyman, Augustin, Hellmut G., Schadendorf, Dirk
Publicado 2013

Characterisation of the changing genomic landscape of metastatic melanoma using cell free DNA

por Cutts, Anthony, Venn, Oliver, Dilthey, Alexander, Gupta, Avinash, Vavoulis, Dimitris, Dreau, Helene, Middleton, Mark, McVean, Gil, Taylor, Jenny C., Schuh, Anna
Publicado 2017